Valeant Obtains Rights to Sculptra

Valeant Pharmaceuticals—a multinational specialty pharmaceutical company—and its subsidiary Valeant International have signed an agreement to acquire Dermik, the United States and Canada-based dermatology unit of Sanofi. Dermik’s portfolio of products includes acne treatment Benzaclin, keratoses treatment Carac and Sculptra facial injectable treatment. As part of the agreement, Valeant will obtain worldwide rights to Sculptra Aesthetic (poly-L-lactic acid).
Valeant International and Valeant Pharmaceuticals North America have also signed an agreement to acquire the assets of Ortho Dermatologic, a division of Janssen Pharmaceuticals, for $345 million. Ortho Dermatologics’ assets include prescription dermatologic products RETIN-A MICRO, ERTACZO and RENOVA.